Why Biotech and Pharma Companies Need Independent Safety Systems for Clinical Trials

Biotech and pharmaceutical companies planning clinical development programs face a critical strategic decision: should they delegate pharmacovigilance and safety monitoring to their contracted CRO, or establish an independent, centralized safety system? While integrating safety with the CRO may offer short-term convenience, a centralized approach provides significant long-term advantages, including regulatory independence, data continuity across multiple CROs, specialized pharmacovigilance expertise, and a stronger foundation for market authorization. This article explores the strategic considerations, implementation approaches, and best practices for establishing an independent safety system that supports your drug development program from early clinical phases through commercialization and post-marketing surveillance.